Trevena's ($TRVN) treatment for pain following abdominoplasty met its goals in a Phase IIb study, clearing the way for late-stage development and sending the company's share price soaring. The intravenous drug, TRV130, is a mu opioid receptor modulator designed to relieve pain following abdominoplasty, or tummy-tuck surgery. In a Phase IIb study involving 200 patients, the drug easily beat out placebo in reducing patient-reported pain and measured up to standard morphine on the same scale. More importantly, TRV130 notched significantly lower rates of vomiting, nausea and breathing problems compared with morphine, stoking hope that Trevena can duplicate the results in Phase III trials slated for next year and eventually hit the market with a disruptive pain treatment. The news sent Trevena's shares up roughly 45% on Tuesday. Release